FDA advisers narrowly vote in favor of Pfizer's RSV vaccine for older adults, despite possible safety concerns

3 years ago 19

Vaccine advisers to the US Food and Drug Administration narrowly voted Tuesday in favor of Pfizer's RSV vaccine for adults over the age of 60, paving the way for approval of the first nation's RSV vaccine, despite some safety concerns.

1. Homepage
2. National News
3. FDA advisers narrowly vote in favor of Pfizer's RSV vaccine for older adults, despite possible safety concerns